Patients Face High Out-of-Pocket Costs After Incident Cancer Diagnosis
Cost increased monotonically with stage at diagnosis, from $462.01 per month for stage 0 to $719.97 per month for stage 4
Inflammation and Nutrition-Based Scores Tied to Prognosis of Low-Risk Myelodysplastic Syndrome
Low Prognostic Nutritional Index and high systemic oxidative stress score independently associated with poorer prognosis
GLP-1 Receptor Agonist Use Linked to Lower Mortality in Seniors With Cancer, T2D
No difference in mortality risk seen for GLP-1 RA and SGLT2i users; significantly lower risk seen for GLP-1 RA versus DPP4i users
Allogeneic HCT Feasible in Older Patients With Myelodysplastic Syndrome
After propensity score matching, overall survival, PFS, nonrelapse mortality did not significantly differ for those 65 years and older versus younger than 65 years
Cancer Anxiety Impacts Family Members of Those Diagnosed With Cancer
Top concerns include life expectancy, course of treatment, and pain
Updated Guidance Improves Staging of HPV-Positive Oropharyngeal Cancer
AJCC9V staging system showed superior hazard consistency, outcome prediction, and balance, but not hazard discrimination
Race Definitions Have Limited Impact on Cancer Rates in Whites, Blacks, Asians
Disparities in cancer rates seen for Native Hawaiians or other Pacific Islanders based on race definitions
Presurgical Immunotherapy Offers Long-Term Benefit in Melanoma
80 percent of adult patients with stage III/IV resectable melanoma remained event-free at four years from the start of neoadjuvant systemic treatment
Many Ineligible for Clinical Trial Could Benefit From Teclistamab for Multiple Myeloma
89 percent of 509 patients would have been ineligible for MajesTEC-1 trial; estimated median PFS was 5.8 months
Most U.S. Adults Lack Awareness of Processed Foods
Authors propose replacing the term 'processed foods' with more specific terms describing foods’ known health effects
